Exisulind

Exisulind

Names
IUPAC name 2-[(1Z)-5-fluoro-1-[(4-methanesulfonylphenyl)methylidene]-2-methyl-1H-inden-3-yl]acetic acid
Identifiers
ChEBI	CHEBI:64212
ChemSpider	4582441
InChI InChI=1S/C20H17FO4S/c1-12-17(9-13-3-6-15(7-4-13)26(2,24)25)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9- Key: MVGSNCBCUWPVDA-MFOYZWKCSA-N InChI=1/C20H17FO4S/c1-12-17(9-13-3-6-15(7-4-13)26(2,24)25)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9- Key: MVGSNCBCUWPVDA-MFOYZWKCBW
Jmol-3D images	Image
PubChem	5472495
SMILES CC1=C(CC(O)=O)C2=C(C=CC(F)=C2)\C1=C/C1=CC=C(C=C1)S(C)(=O)=O
Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
Infobox references

Exisulind is a drug used to treat cancer. It acts by inhibiting the enzyme cyclic guanosine monophosphate phosphodiesterase. Trademark by OSI Pharmaceuticals is Aptosyn. NCBI PubChem ID 5472495. Also listed as Sulindac sulfone which is a metabolic product of Sulindac (see).